focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 23.25
Bid: 23.00
Ask: 23.50
Change: 2.00 (9.41%)
Spread: 0.50 (2.174%)
Open: 20.75
High: 23.50
Low: 20.50
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Angle CEO, finance chief join capital raise

Tue, 19th Jul 2022 16:35

(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.

The AIM-traded firm said CEO Andrew Newland bought 125,000 shares for 80p each, spending a total of £100,000.

At the same time, its CFO Ian Griffiths spent £30,000 on 37,500 shares, also at 80p apiece.

Both transactions took place off-market, as part of the company's capital raise of £20.13m through a placing, retail offer and management subscription, announced on Friday.

Reporting by Josh White at Sharecast.com.

Top Director Buys

Alphawave Ip Group (AWE)

Director name: Sutardja,Sehat

Amount purchased: 538,867 @ 121.84p

Value: £656,555.55

Angle (AGL)

Director name: Newland,Andrew D

Amount purchased: 125,000 @ 80.00p

Value: £100,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 887.70p

Value: £88,770.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 871.54p

Value: £87,154.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 4,000 @ 877.10p

Value: £35,084.00

Angle (AGL)

Director name: Griffiths,Ian F

Amount purchased: 37,500 @ 80.00p

Value: £30,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,816 @ 887.54p

Value: £24,993.13

Schroder British Opportunities Trust (SBO)

Director name: Bartlett,Diana Dyer

Amount purchased: 26,345 @ 75.50p

Value: £19,890.47

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 960.00p

Value: £19,200.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 956.58p

Value: £19,131.60

More Acquisitions (TMOR)

Director name: McIllree ,Roderick

Amount purchased: 2,000,000 @ 0.95p

Value: £18,900.00

Schroder British Opportunities Trust (SBO)

Director name: England,Neil

Amount purchased: 25,000 @ 75.15p

Value: £18,787.50

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,218 @ 820.00p

Value: £9,987.60

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,410 @ 708.25p

Value: £9,986.32

Audioboom Group (BOOM)

Director name: Tobin,Michael

Amount purchased: 1,117 @ 850.00p

Value: £9,494.50

Genflow Biosciences (GENF)

Director name: Leire,Eric

Amount purchased: 308,999 @ 3.03p

Value: £9,362.67

Velocys Plc (VLS)

Director name: Sanderson,Philip

Amount purchased: 200,000 @ 4.30p

Value: £8,600.00

Time Finance (TIME)

Director name: Roberts ,James

Amount purchased: 26,972 @ 18.50p

Value: £4,989.82

Schroder British Opportunities Trust (SBO)

Director name: Jenkinson,Tim

Amount purchased: 6,609 @ 75.15p

Value: £4,966.53

Schroder British Opportunities Trust (SBO)

Director name: OBE,Christopher Keljik,

Amount purchased: 6,577 @ 75.50p

Value: £4,965.50

Time Finance (TIME)

Director name: Telling,Julian

Amount purchased: 26,000 @ 18.85p

Value: £4,901.00

Coca-cola Hbc Ag (cdi) (CCH)

Director name: Bogdanovic,Zoran

Amount purchased: 218 @ 1,956.75p

Value: £4,265.71

Time Finance (TIME)

Director name: Raynes ,Tanya

Amount purchased: 21,156 @ 18.85p

Value: £3,987.91

Bae Systems (BA.)

Director name: Woodburn,Charles

Amount purchased: 19 @ 804.96p

Value: £152.94

Bae Systems (BA.)

Director name: Greve,Brad

Amount purchased: 19 @ 804.96p

Value: £152.94

(HWG)

Director name: Birch,Chris

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Patmore,Katerina

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Shillaw,Lynda

Amount purchased: 107 @ 140.00p

Value: £149.80

More News
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.